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Study Design 1 
The trial is a prospective randomised controlled interventional trial (ISRCTN19392591). Enrolment of patients 2 
took place in two intensive care units within the Department of Anesthesiology and Operative Intensive Care 3 
Medicine (CCM, CVK) at Charité - Universitätsmedizin Berlin, Germany. The Charité institutional review board 4 
granted ethical approval (Charité EA 2/041/10).  5 
Participants 6 
Inclusion criteria: 7 
• Mechanical ventilation 8 
• SOFA ≥ 9 within the first 72 hours after ICU admission 9 
Exclusion criteria: 10 
• age < 18 years 11 
• insulin-dependent diabetes mellitus 12 
• body-mass-index > 35 kg/m2 13 
• preexisting neuromuscular disease 14 
• moribund health status 15 
• participation in another clinical trial 16 
• prior ICU treatment or mechanical ventilation for more than 72 hours before inclusion 17 
• pregnancy 18 
• not ambulating before admission 19 
Enrolment process 20 
Patients were screened daily on ward rounds through participating ICUs by study physicians for eligibility to be 21 
enrolled into the trial. In case of fulfillment of all inclusion criteria without applicability of an exclusion criterion 22 
the legal proxy was approached for enrolment into the trial. 23 
Muscle biopsy samples (n = 6) from patients undergoing elective orthopedic surgery but who were otherwise 24 
healthy were included as references to determine baseline values. Similarly, plasma sampls from healthy 25 
volunteers were included to determine baseline values for myostatin plasma concentrations (n = 91).  26 
Randomisation  27 
Primary randomisation with a 1:2 ratio into two groups of 30 [control group and intervention group] was done 28 
with sealed opaque envelopes. Sequential allocation of patients to first NMES + WBV, second NMES and, third 29 
 
 
4 
WBV within the intervention group was done for further subrandomisation. Study staff was blinded during the 1 
assessment of all outcome parameters and had no influence on treatment decisions. 2 
Procedures 3 
General ICU treatment adhered to published standard operating procedures [1-3]. 4 
Protocols for performed interventions 5 
Protocol-based physiotherapy 6 
Protocol-based physiotherapy was performed twice daily for 25/35 minutes by a trained and dedicated study 7 
physiotherapist seven days a week. Further muscle activating measures were performed daily by trained study 8 
staff as described below. Every morning the mobilisation goal was defined by a multiprofessional case conference 9 
considering patients ability to participate in terms of consciousness, haemodynamic stability and respiratory 10 
stability as outlined in Supplement Table S1.  11 
  12 
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Table S1 Physiotherapy protocol 1 
Level of 
mobilisation 
Level 1 Level 2 Level 3 Level 4 Level 5 
Description of 
the level of 
mobilisation 
according to 
patient’s status 
RASS: -5 
• 
haemodynamically 
unstable  
• respiratorically 
unstable 
• ICP not 
compensable 
• "minimal-
handling" 
RASS: -5 to -4 
• 
haemodynamically 
stable 
• respiratorically 
stable 
• ICP stable 
RASS: -3 to -2 
• 
haemodynamically 
stable 
• respiratorically 
stable 
• ICP stable 
• active 
participation 
RASS: ≥-2 
• 
haemodynamically 
stable 
• respiratorically 
stable 
• ICP stable 
• active 
participation 
RASS: ≥-1 
• no intensive care 
monitoring 
necessary 
• transfer to 
general ward 
planned 
Mobilisation Ø • passive 
mobilisation of 
upper and lower 
extremities 
• passive 
mobilisation 
• assistive 
mobilisation 
• active 
mobilisation 
• passive 
mobilisation 
• assistive 
mobilisation 
• active 
mobilisation 
• activities of daily 
living 
• passive 
mobilisation 
• assistive 
mobilisation 
• active 
mobilisation 
• activities of daily 
living  
• intensified 
therapy 
Respiratory 
therapy 
Ø • as medically 
indicated 
• pneumonia and 
atelectasis 
prophylaxis 
• as medically 
indicated 
• pneumonia and 
atelectasis 
prophylaxis 
as medically 
indicated 
• pneumonia and 
atelectasis 
prophylaxis 
as medically 
indicated 
• pneumonia and 
atelectasis 
prophylaxis 
Active transfer Ø Ø  • increasing 
mobility within the 
bed  
• supine → lateral 
→ sitting → 
standing (assistive 
•• supine → lateral 
→ sitting → 
standing (assistive 
 
 
6 
(Mobilisation with 
participation of 
the patient) 
devices are 
permitted)  
devices are 
permitted) 
Mobility training Ø Ø  Ø  yes  yes 
Passive transfer 
(Mobilisation 
without 
participation of 
the patient) 
Ø • sitting in the 
Thekla®* 
• standing in the 
Thekla® * 
• sitting in the 
Thekla®* 
• standing in the 
Thekla®* 
If necessary 
• sitting in the 
Thekla®* 
• standing in the 
Thekla®* 
If necessary 
• sitting in the 
Thekla®* 
• standing in the 
Thekla®* 
Positioning 
therapy 
• Prophylaxis 
• specific 
positioning 
• Prophylaxis 
• specific 
positioning 
• Prophylaxis 
• specific 
positioning 
• Prophylaxis 
• specific 
positioning 
• Prophylaxis as 
required  
• specific 
positioning 
Frequency NA • 2x daily • 2x daily • 2x daily • 2x daily 
Duration per 
session 
NA • 25-35 minutes  25-35 minutes 25-35 minutes  25-35 minutes 
*Thekla® refers to a chair produced by Hanse-Medizintechnik, which was developed as an assistive device that 
enables passively transferring an unconscious patient from supine into upright standing position. 
 
Protocol for neuromuscular electrical stimulation 1 
Neuromuscular electrical stimulation (NMES) was performed bilaterally on 8 different muscle groups (M. tibialis 2 
anterior, M. triceps surae, M. vastus lateralis, posterior thigh, M. biceps brachii, M. triceps brachii, wrist extensors, 3 
wrist flexors) daily for 20 minutes starting on the day of enrolment (MUSKELaktiv 2-Kanal, schwa-medico®, 4 
Germany; Physiomed-Expert-2-Kanal, Physiomed®, Germany). Electrical impulses of 350 µs at 50 Hs with a 5 
ramp of 1 second and an on-time of 6/10 seconds as well as an off-time of 10/15 seconds. Electrical current was 6 
increased to maximal 70 mA until visible or palpable muscle contraction in unconscious respectively contraction 7 
or discomfort in awake patients occurred. If no contraction could be observed NMES was performed with 40 mA. 8 
Protocol for Whole-body vibration 9 
Whole-body vibration was performed daily for 20 cycles (alternating stimulation, 26 Hs, amplitude 15 mm) with 10 
one minute stimulation and a one minute break using the Galileo® (Novotec®, Germany) instrument. To assure a 11 
complete patient-instrument coupling haemodynamically stable patients were brought into an almost upright 12 
 
 
7 
position (80-90° with 90° meaning upper body was perpendicular to the floor) with the use of a Thekla® (Hanse-1 
Medizintechnik, Germany) while lightly flexing their knees (0/10°). Haemodynamically unstable patients received 2 
whole-body vibration within the bed with head raised and legs lowered up to 30°. Furthermore, to ensure patient-3 
instrument coupling knees and hips were flexed lightly (knees: 0/10° and hip: 10/30°). 4 
Protocol for first adequate awakening and MRC 5 
Screening for adequate awakening was performed daily by study physicians. In order to be classified as adequately 6 
awake a patient had to have a Richmond Agitation and Sedation Score between -1 and +1 as well as an adequate 7 
response to three out of the five following verbal commands: “Open/close your eyes,” “Look at me,” “Open your 8 
mouth and put out your tongue,” “Nod your head,” and “Raise your eyebrows  when I have counted up to 5.” on 9 
two consecutive days as previously published by DeJonghe et al.[4]. Medical Research Council score was assessed 10 
by trained study staff on a 6 point scale (0 no visible or palpable contraction; 1 visible or palpable contraction 11 
without limb movement; 2 movement without gravity; 3 movement against gravity; 4 movement against 12 
resistance; 5 full force) in 8 different muscle groups bilaterally (wrist extension, wrist flexion, elbow extension, 13 
elbow flexion, should aberduction, hip flexion, knee extension, ankle extension, ankle flexion). The sum score was 14 
divided by the number of muscle examined.  15 
Protocols for performed analyses 16 
Protocol for muscle biopsy and histological analyses 17 
Muscle biopsy specimen were obtained 15 days after onset of critical illness respectively the closest day to this 18 
date in case of any circumstances not allowing muscle biopsy on the predefined date (Ethical approval: Charité 19 
EA 2/041/10). Afterwards Lidocain was administered as a local anaesthetic to the incision site located in the distal 20 
third of the Vastus lateralis muscle. A surgical incision through skin and fascia was done to expose muscle tissue 21 
and retrieve the muscle biopsy specimen. If necessary bleeding was stopped and the wound was closed as well as 22 
dressed. We obtained biopsy specimens from 11 patients in the control group and 26 patients in the intervention 23 
group. Furthermore 6 control biopsy specimens were obtained from volunteers undergoing elective orthopaedic 24 
surgery. 25 
For gene expression and protein analyses biopsy specimens were directly snap frosen in liquid nitrogen and for 26 
immunohistochemistry and metachromatic ATPase staining they were mounted and frozen under cryoprotection. 27 
Specimens were stored at -80°C.  28 
Biopsy specimens for histological analyses (Haematoxylin & Eosin or Gomori trichrome) were fixed in 3.7% 29 
paraformaldehyde, embedded into paraffin and sectioned using a cryotome (Leica CM3050 S) into 10 µm thick 30 
sections. Haematoxylin and Eosin and Gomori trichrome staining was performed as recently published [5-9].  For 31 
 
 
8 
metachromatic ATPase staining muscle biopsy specimens were embedded in tissue-freezing medium (Triangle 1 
Biomedical Sciences, Durham, NC) supplemented with gum tragacanth (Sigma, St. Louis, MO). Subsequently the 2 
samples were immediately frozen in liquid nitrogen-cooled isopentane (2-Methylbutan; Fa. Carl Roth) and stored 3 
afterwards in liquid nitrogen until sectioning. Mounted tissue samples were sectioned with a cryotome (Leica 4 
CM3050 S, 10 µm) for metachromatic ATPase staining which was performed as previously published [5, 8, 10]. 5 
Myocyte cross sectional area was determined on pictures of histological sections of in average 115.5 (IQR: 106 - 6 
136) myofibers per patient from 6 control patients, 19 patients in the standard physiotherapy group, 11 patients in 7 
the control group and 25 patients in the intervention group with Image J (Version 1.47v). 8 
GLUT4 immunohistochemical stains were performed with a rabbit anti-GLUT4 antiserum (1154p) provided by 9 
Hoffmann-La Roche. 10 
Protocol for quantification of gene expression 11 
TRIzol® Reagent (Invitrogen) was used to extract total RNA from muscle biopsy specimens according to the 12 
manufacturer’s protocol and as recently published [[5, 6, 9]. Reverse-transcription of 1 µg RNA into cDNA was 13 
performed by using the SuperScript® First-Strand Synthesis System (Invitrogen) according to the manufacturers 14 
protocol and as recently published [5, 6, 8, 9]. TaqMan® Universal PCR Mastermix (Applied Biosystems) was 15 
used for real-time polymerase chain reaction (RT-PCR) together with commercially available primer and probe 16 
sets (Applied Biosystems) (see Table S2). Step-OneTM Plus thermocycler (Applied Biosystems) was used for all 17 
PCR reactions. All experiments were conducted as manufacturer’s instructions stated. Glyceraldehyde-3-18 
phosphate dehydrogenase (GAPDH) gene expression was used to normalise gene expression, in order to correct 19 
for a variance in mRNA extraction and cDNA synthesis efficiency between samples. For normalisation values of 20 
volunteers undergoing elective orthopaedic surgery were set as one and patient values were expressed as fold 21 
change [5, 8, 10]. 22 
Table S2 Specifications of gene expression assays from Applied Biosystems 23 
Gene name Catalogue number 
MYH1 Hs00428600_m1 
MYH2 Hs00430042_m1 
MYH4 Hs00757977_m1 
TRIM63 Hs00822397_m1 
TRIM62 Hs00217089_m1 
FBXO32 Hs00369714_m1 
 
 
9 
MYH indicates myosin heavy chain; TRIM, tripartite motif containing protein and FBXO, F-box containing 
protein. 
Protocol for protein analyses 1 
All protein analyses were performed as previously published [5, 8, 10].  Skeletal muscle biopsy specimen were 2 
homogenised (30s, 2000 rpm) in ice-cold extraction buffer 1:3 wt/vol (10 mM Tris HCl, pH 7.5, 140 mM NaCl, 1 3 
mM EDTA, 25% glycerol, 0.5% sodium dodecyl sulfate (SDS), 0.5% Nonident P-40) supplemented with 0.1 mM 4 
dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and 100 ng/ml protease inhibitor cocktail (Roche). Clearing 5 
was done through centrifugation (4°C, 10 min, 14000 rpm). The supernatant was assayed for protein concentration 6 
using Bio-Rad Protein Assay and stored at -80°C until analyses. SDS polyacrylamide gel electrophoresis (SDS-7 
PAGE) was used to separate proteins according to their molecular weight. Afterwards proteins were blotted onto 8 
nitrocellulose or PVDF membranes (Amersham Pharmacia Biotech). Primary and secondary antibodies used are 9 
shown in Table S3. Visualisation was performed by enhanced chemiluminescence (ECL) detection reagent 10 
(Amersham Pharmacia Biotech).  11 
Table S3 Specification for antibodies used for Western Blots 12 
Antibody Clone Manufacturer Concentration Membrane 
anti-total Myosin heavy chain MF20 Sigma 1:3000 nitrocellulose 
anti-fast Myosin heavy chain MY32 Sigma 1:3000 nitrocellulose 
anti-slow Myosin heavy chain NOQ7 Sigma 1:3000 nitrocellulose 
anti-MuRF1  R&D 1:200 PVDF 
anti-Atrogin1  Abcam 1:500 PVDF 
anti-mouse IgG HRP  CellSignaling 1:3000  
anti-goat IgG HRP  Abcam 1:3000  
 13 
Plasma analysis 14 
Myostatin plasma concentration were analysed with R&D Systems GDF-8/Myostatin Quantikine ELISA Kit 15 
(Catalogue number DGF80) 16 
 17 
Statistics 18 
Counts and percentages are used to present categorical variables and median and interquartile range to present 19 
metric variables. Due to small group size non-normal distribution was assumed. Statistic test were selected 20 
accordingly. Specifically, non-parametric tests for metric variables and differences between groups. Kruskal-21 
 
 
10 
Wallis and Mann-Whitney U tests were used for independent samples and Wilcoxon signed-rank test test for 1 
dependent samples.  Chi-Square test was used for group differences and categorical variables. P < 0.05 was 2 
accepted as significant. Myocyte cross sectional area shift was analysed through ANOVA and validated through 3 
Welch- and Brown-Forsythe test in case of inhomogenous variance tested by the Levene’s Test. Statistical analyses 4 
were performed with SPSS IBM (version 25), and graphics were created with GraphPad Prism (version 7.0) and 5 
Sigma Plot (version 12.0). 6 
  7 
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Supplement results:  1 
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Fig. S1 Muscle strength and functional independence. a Medical Research Council score (MRC) increased significantly between first awakening and discharge in both groups. A 
further increase between discharge and 12-month follo-up could only be observed for the intervention group. The dotted black line indicates an MRC score cut-off value of 4 for 
ICUAW diagnosis. b Relative hand grip strength also increased significantly between first awakening and discharge in both groups while a further increase until 12-month could only 
be observed for the intervention group. The dotted black line indicates reference values for age and gender matched references. c 6 minute walking distance was reduced in both 
groups at 12-month follow-up. The dotted black line indicates reference values for age and gender matched references. Data are shown as box plots with median and interquartile 
range. Statistical significance between groups was tested with Mann-Whitney U Test and between timepoints with Wilcoxon-Test.
! represent outliers which are more than 1.5  interquartile ranges above or below the first or third quartile.
a) b) c)
Control
Intervention
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 Table S4 Fiber type distribution 1 
 
 
 
Values represent frequency of fiber types and are presented as median and interquartile range. Statistical 
significance was tested with Kruskal-Wallis-Test  
 
Control Intervention p-value 
Type I 20.5 [16.0/25.3] 23.6 [17.5/26.7] 0.399 
Type IIa 46.4 [39.1/63.4] 44.3 [31.7/54.8] 0.140 
Type IIb 26.5 [16.7/45.2] 31.7 [19.6/41.6] 0.124 
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